drugset
Drugs / JK08
last change Feb 2026 re-read 2 minutes ago

JK08

Protein / enzyme biologic targets CTLA4

Developed for
clear cell renal carcinoma · colorectal adenocarcinoma · gastric adenocarcinoma · gastroesophageal cancer · head and neck squamous cell carcinoma · hepatocellular carcinoma · malignant epithelial tumor of ovary · melanoma
+9 more · metastatic malignant neoplasm · non-small cell lung carcinoma · pancreatic adenocarcinoma · papillary renal cell carcinoma · skin squamous cell carcinoma · small cell lung carcinoma · thyroid cancer · triple-negative breast carcinoma · urothelial carcinoma
Investigated by
Salubris Biotherapeutics Inc

Trials 1 · a red edge is where a trial was stopped

today NCT05620134 · Ph 1/2
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05620134 Oct 2022 → Oct 2025 overdue clear cell renal carcinoma, colorectal adenocarcinoma, gastric adenocarcinoma, gastroesophageal cancer +13 Salubris Biotherapeutics Inc Active not recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as JK08 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05620134 ↗
Modality Protein / enzyme biologic “Recombinant fusion protein consisting of two functional elements” NCT05620134 ↗
Route Subcutaneous “subcutaneously administered JK08” NCT05620134 ↗
Target CTLA4 “directed against CTLA-4” NCT05620134 ↗